Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


UK’s NICE Says ‘Light Touch’ HTA Evaluation Will Support Innovation

Executive Summary

The UK’s health technology assessment body recognizes that its traditional product evaluation processes are too slow for innovative medtech products. Its new “conditional recommendation” pathway aims to fix this.

You may also be interested in...

How Innovative UTI Diagnostics Can Help Combat Antibiotic Resistance

UTIs are one of the most common reasons for antibiotics to be prescribed, but accurate and timely diagnostic tools are lacking. England’s NICE has identified four innovative IVDs that could be rolled out for NHS patients, but said more research is needed on these products first.

UK Trials Reimbursement Of Digital Self-Help Apps For Children With Anxiety

Five digital mental health apps for children with low mood and anxiety are set to receive interim reimbursement via the UK’s early value assessment (EVA) pilot in a bid to tackle staff shortages and long waiting times for current interventions.

UK’s NICE Outlines Standards That AI and Data-Driven Medtech Should Meet For NHS Uptake

NICE, the body that produces health technology assessment guidance for England and Wales, has earlier this month introduced updates to its evidence standards guidance for developers of digital technologies based on artificial intelligence (AI) and on adaptive algorithms.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts